Q/C Technologies

Q/C Technologies is building a proprietary optical computing architecture to outpace traditional GPUs faster, more energy-efficient, and scalable. Strategic IP and top talent are at the core. Learn more: bit.ly/4sVXUCg $QCLS

Electronic GPUs are hitting limits as AI workloads grow. Q/C Technologies’ new Optical Processing Unit initiative uses photons to reduce energy use, improve speed, and scale AI workloads more efficiently. Read more: bit.ly/4sVXUCg $QCLS

Today, Q/C Technologies announced a new Optical Processing Unit (OPU) initiative, advancing photonic computing to address key AI infrastructure bottlenecks in performance, scalability and energy use. Read more: bit.ly/4sVXUCg $QCLS

We are pleased to welcome AI systems leader Chelsea Voss (@csvoss) to our Board of Directors. Her expertise in advanced computation and large-scale systems will be key as we advance our quantum-class computing strategy. Read the press release: bit.ly/4bHdkEW $QCLS

Martin Shkreli has joined $QCLS as a Strategic Advisor, bringing experience in tech development and financial innovation. His perspective supports Q/C’s quantum-class, photonic computing strategy and the commercialization of its qc-LPU100™ platform. bit.ly/3YisVmo

Today, we are pleased to welcome @MartinShkreli as part of our expanding advisory team alongside @jaltucher, further strengthening the company’s depth of expertise across #computing, #AI, and #blockchain technologies. Read the press release: bit.ly/3YisVmo $QCLS

$QCLS introduced a proprietary qc-LPU100™ brand of quantum-class laser processing units with LightSolver. The breakthrough LPUs will be designed to tackle high energy consumption and rising operational costs. ICYMI: bit.ly/47y91Z6 #QuantumComputing #Tech #AI #Crypto

Q/C Technologies 🤝 @lightsolverco. Introducing the qc-LPU100™—a Q/C-branded implementation that harnesses the natural properties of light with the goal of achieving first-in-class computational speed and energy. Read more: bit.ly/47y91Z6 $QCLS #QuantumComputing #Tech

Q/C Technologies is honored to welcome Technion Professor Dr. Steven Frankel as Senior Quantum Advisor to advance photonic and quantum-class computing initiatives. Read the press release: bit.ly/3J2UFaU $QCLS #Photonics #QuantumComputing

Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol $QCLS, representing recent strategic pivot into quantum-class computing. Read the press release: bwnews.pr/3VCEALF #Photonics #QuantumComputing #Crypto

Today, we are pleased to announce name change to Q/C Technologies and new ticker symbol $QCLS to reflect our strategic focus on #quantum class #photonic #computing, effective Thursday, September 25, 2025. Read the press release: bit.ly/4nv01dG $TNFA

TNF Pharmaceuticals is pleased to have regained compliance with Nasdaq’s listing standards. This milestone comes as we work to build a strong strategic platform for growth and shareholder value. Read the press release: bit.ly/4gra1Cl $TNFA

TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference. Read the press release here: bit.ly/3VCXCkZ $TNFA @HCWCO #HCWConference

TNF Pharmaceuticals Announces Closing of $7 Million Private Placement. Read the press release here: bit.ly/4p1H5o9 $TNFA #BusinessUpdate

TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications. Read the press release here: bit.ly/47V6x8D $TNFA #Crypto #HPC #PhotonicComputing

TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation. Read the press release here: bit.ly/3Hkuvj7 $TNFA #BusinessUpdate

"The body of evidence surrounding DADA2 has shown that TNF inhibition is the most effective treatment for the hyperinflammatory and vasculitic aspects of this disease," said Mitchell Glass, M.D., TNF CMO. bit.ly/4eo3jMs $TNFA #TNFInhibition #RareDisease #Vasculitis

TNF formed a philanthropic collaboration with the @dada2foundation to initiate a Compassionate Use study evaluating isomyosamine as a potential treatment for #DADA2. Read more: bit.ly/4eo3jMs $TNFA #TNFInhibitor #Immunology #RareDisease

TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease. Read the press release: bit.ly/4eo3jMs $TNFA #RareDisease #Immunology #ClinicalResearch

TNF CMO Mitchell Glass, M.D., comments: “Our goal for our #GLP1 study series is to identify patients who are taking GLP-1 agonists to test whether isomyosamine can decrease inflammation and prevent or ameliorate the risk of adverse outcomes.” bit.ly/4dbw7an $TNFA